戻る
Genmab A/S (GMAB)価格
GMAB 株価推移チャート
GMAB 収入
Genmab A/S
$31.33
-2.85%
$-0.92
終値： Jan 20, 16:00:00 GMT-5
$31.4
0.22%
$0.07
アフターマーケット：Jan 20, 20:00:00 GMT-5
主要データ
前終値
$32.25
始値
$31.38
当日レンジ
$31.05 - $31.68
52週レンジ
$17.23 - $35.43
取引高
2.7M
平均取引高
1.8M
1株当たり利益(TTM)
2.29
配当利回り
--
時価総額
$19.3B
Genmab A/Sとは何ですか？
Genmab A/S is an international biotechnology company, which engages in the development of human antibody therapeutics for the treatment of cancer and other diseases. The company specializes in the creation and development of antibody therapeutics for the treatment of cancer. The firm is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA (teprotumumab) for the treatment of thyroid eye disease and FASPRO, for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy Arzerra, approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Genmab develops a broad clinical and pre-clinical product pipeline, and owns four antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.